Literature DB >> 7535815

Self-reactive T cell hybridomas and tolerance. Same range of antigen dose dependence but higher numbers of self-reactive T cell hybridomas from mice in which self-tolerance has been broken by antiserum treatment.

S C Schneider1, N A Mitchison.   

Abstract

Mechanisms of self-tolerance of 4-hydroxyphenylpyruvate dioxygenase (HPPD) are explored. It is well established that negative selection based on TCR affinity occurs in the thymus. We have investigated the frequency with which self-reactive T cell hybridomas can be obtained in relation to self-tolerance. Mice immunized with the self-form of HPPD gave rise to T cell hybridomas that were able to recognize self-protein and a synthetic peptide representing the T cell epitope, at higher Ag concentration than was necessary for recognition of allo-protein. The efficiency of negative selection was then reduced by treating neonatal mice with anti-HPPD antiserum. This reduced T cell tolerance of the self-protein, as judged by in vitro proliferation, and enabled self-reactive T cell hybridomas to be generated at a higher frequency. However, the Ag concentration requirements of these hybridomas for the self-protein and the self-peptide remained unaltered. The possibility that these findings reflect an auxiliary mechanism of self-tolerance based on frequencies of self-reactive T cells is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535815

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  Regulation by non-major histocompatibility complex genes of the allo-4-hydroxy-phenylpyruvate dioxygenase (F liver protein) response.

Authors:  M C Brunner; N A Mitchison
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

2.  Sequence similarity and structural homologies are involved in the autoimmune response elicited by mouse hepatitis virus A59.

Authors:  Patricia A Mathieu; Karina A Gómez; Jean-Paul Coutelier; Lilia A Retegui
Journal:  J Autoimmun       Date:  2004-09       Impact factor: 7.094

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.